{"organizations": [], "uuid": "b67229fc3b072157df56466c38f3215d97465efc", "thread": {"social": {"gplus": {"shares": 0}, "pinterest": {"shares": 0}, "vk": {"shares": 0}, "linkedin": {"shares": 0}, "facebook": {"likes": 0, "shares": 0, "comments": 0}, "stumbledupon": {"shares": 0}}, "site_full": "www.reuters.com", "main_image": "https://s4.reutersmedia.net/resources_v2/images/rcom-default.png", "site_section": "http://www.reuters.com/resources/archive/us/20180125.html", "section_title": "Archive News &amp; Video for Thursday, 25 Jan 2018 | Reuters.com", "url": "https://www.reuters.com/article/brief-dechra-pharmaceuticals-to-acquire/brief-dechra-pharmaceuticals-to-acquire-ast-farma-and-le-vet-idUSFWN1PK0ER", "country": "US", "domain_rank": 408, "title": "BRIEF-Dechra Pharmaceuticals to acquire Ast Farma and Le Vet", "performance_score": 0, "site": "reuters.com", "participants_count": 1, "title_full": "", "spam_score": 0.0, "site_type": "news", "published": "2018-01-25T15:06:00.000+02:00", "replies_count": 0, "uuid": "b67229fc3b072157df56466c38f3215d97465efc"}, "author": "Reuters Editorial", "url": "https://www.reuters.com/article/brief-dechra-pharmaceuticals-to-acquire/brief-dechra-pharmaceuticals-to-acquire-ast-farma-and-le-vet-idUSFWN1PK0ER", "ord_in_thread": 0, "title": "BRIEF-Dechra Pharmaceuticals to acquire Ast Farma and Le Vet", "locations": [], "entities": {"persons": [], "locations": [{"name": "europe", "sentiment": "none"}], "organizations": [{"name": "reuters", "sentiment": "negative"}, {"name": "ast farma", "sentiment": "negative"}, {"name": "dechra pharmaceuticals plc", "sentiment": "negative"}, {"name": "brief-dechra pharmaceuticals", "sentiment": "negative"}, {"name": "eikon", "sentiment": "none"}]}, "highlightText": "", "language": "english", "persons": [], "text": "Jan 25 (Reuters) - Dechra Pharmaceuticals Plc:\n* ‍BOARD OF DECHRA, INTERNATIONAL VETERINARY PHARMACEUTICAL BUSINESS, IS PLEASED TO ANNOUNCE THAT IT HAS ENTERED INTO A CONDITIONAL ACQUISITION AGREEMENT TO ACQUIRE AST FARMA AND LE VET FOR A TOTAL CONSIDERATION OF EUR 340.0 MILLION ON A DEBT-FREE AND CASH-FREE BASIS​\n* ‍TOTAL CONSIDERATION WILL BE SATISFIED APPROXIMATELY 75 PERCENT IN CASH AND 25 PERCENT IN NEW DECHRA SHARES, WHICH ARE SUBJECT TO A TWO YEAR LOCK-IN​\n* ‍ACQUISITION STRENGTHENS DECHRA‘S PORTFOLIO IN NETHERLANDS AND ACROSS EUROPE​\n* ACQUISITION GIVES ACCESS TO A ROBUST PIPELINE OF PRODUCTS​\n* ACQUISITION GIVES ‍SYNERGY BENEFITS PARTICULARLY IN FORM OF REVENUE SYNERGIES​\n* ‍CHIEF EXECUTIVE SAYS “ACQUISITION IS A RARE OPPORTUNITY TO STRENGTHEN OUR EU SEGMENT IN ALL MAJOR EUROPEAN COUNTRIES IN WHICH WE OPERATE”.​\n* ‍NET PROCEEDS OF PLACING WILL BE USED TO FUND ACQUISITION IN PART. REMAINING ACQUISITION CONSIDERATION IS BEING FUNDED THROUGH ISSUE OF 3,670,625 NEW ORDINARY SHARES TO SELLERS AND DRAWDOWN UNDER A NEW BANKING FACILITY​ Source text for Eikon: Further company coverage: (Reporting by Emma Rumney)\n ", "external_links": ["http://thomsonreuters.com/en/about-us/trust-principles.html"], "published": "2018-01-25T15:06:00.000+02:00", "crawled": "2018-01-26T21:16:10.005+02:00", "highlightTitle": ""}